25 May 2013
Keywords: mixed, ph, ii, data, astrazeneca, recentin, anglo-swedish
Article | 03 March 2008
Anglo-Swedish drug major AstraZeneca says that its HORIZON III Phase
II/III head-to-head study of Recentin (cediranib) with chemotherapy
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 March 2008
24 May 2013
© 2013 thepharmaletter.com